SecBot SecBot
6-K ·Filed Apr 20, 2026

GLAXF

GSK plc
NEUTRAL
Impact 3/10
Horizonimmediate Processed6mo ago SEC0001654954-26-003688
Notable filing: 6-K
Actionable Insight • Neutral

This is a routine share buyback under an existing program. The impact on the stock price is likely to be minimal. Monitor the company's cash flow and future buyback announcements for any changes in capital allocation strategy.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
GLAXF ▼ -10.88% at T+60d
NEUTRAL call -10.88% · α vs SPY -17.66% · entry $29.50 → $26.29
Entry = T+0 close
Apr 20, 2026
via day close
T+1d
0.00%
call 0.00% · α +0.65%
$29.50
settled 6mo ago
T+5d
-10.51%
call -10.51% · α -11.42%
$26.40
settled 6mo ago
T+20d
-12.88%
call -12.88% · α -17.08%
$25.70
settled 5mo ago
T+60d
-10.88%
call -10.88% · α -17.66%
$26.29
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

GSK plc repurchased 330,000 ordinary shares on April 17, 2026, at an average price of 2,126.15 GBp per share, as part of its ongoing buyback program. Since the program's inception on February 17, 2026, the company has acquired 19,856,521 shares. The purchased shares will be held as treasury shares, increasing the total to 259,747,615, which represents 6.40% of voting rights.

Key Facts

  • GSK repurchased 330,000 ordinary shares on April 17, 2026.
  • The average price paid was 2,126.15 GBp per share, with prices ranging from 2,115.00 GBp to 2,137.00 GBp.
  • The repurchase was conducted through BNP Paribas SA on the London Stock Exchange and CBOE Europe Limited.
  • Since the buyback program began on February 17, 2026, GSK has purchased 19,856,521 shares.
  • The total number of treasury shares now stands at 259,747,615, representing 6.40% of voting rights.

Financial Impact

The repurchase of 330,000 shares at an average price of 2,126.15 GBp implies a total cost of approximately £7.02 million (330,000 * 2,126.15 / 100).

cashshares outstanding

Risk Factors

  • The buyback program could be suspended or terminated, which might be perceived negatively by the market.
  • The use of cash for buybacks reduces funds available for other purposes such as dividends, R&D, or acquisitions.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-003688
Document: 0001654954-26-003688-index-headers.html0001654954-26-003688
Document: 0001654954-26-003688-index.html0001654954-26-003688
Document: 0001654954-26-003688.txt0001654954-26-003688
51 reports for GLAXF
Performance horizon
46% Hit rate @ T+5 6 of 13 directional calls Went positive at some point 7 of 13 best @ T+20▲ +9.49%Jun 9, 2026
Filters
Rows
Reports for GLAXF — sortable, filterable
TypeNow
Jun 10, 2026
19w ago
6-K
NEUTRAL ★ 1/10
$25.12 $25.25▲ +0.52%▼ −1.62%$26.12 (+3.98%)
Jun 9, 2026
19w ago
6-K
NEUTRAL ★ 1/10
$24.66 $25.50▲ +3.41%▲ +1.60%$26.12 (+5.92%)
Jun 9, 2026
20w ago
6-K
BULLISH ★ 7/10
$24.66 $25.50▲ +3.41%▲ +1.60%$26.12 (+5.92%)
Jun 1, 2026
21w ago
6-K
NEUTRAL ★ 1/10
$24.25 $24.66▲ +1.69%▲ +4.44%$26.12 (+7.71%)
Jun 1, 2026
21w ago
6-K
NEUTRAL ★ 2/10
$24.25 $24.66▲ +1.69%▲ +4.44%$26.12 (+7.71%)
May 28, 2026
21w ago
6-K
BULLISH ★ 7/10
$24.58 $24.66▲ +0.33%▲ +0.01%$26.12 (+6.27%)
May 27, 2026
21w ago
6-K
NEUTRAL ★ 1/10
$25.57 $23.94▼ −6.37%▼ −7.58%$26.12 (+2.15%)
May 26, 2026
22w ago
6-K
NEUTRAL ★ 1/10
$25.50 $24.25▼ −4.90%▼ −5.99%$26.12 (+2.43%)
May 26, 2026
22w ago
6-K
NEUTRAL ★ 2/10
$25.50 $24.25▼ −4.90%▼ −5.99%$26.12 (+2.43%)
May 22, 2026
22w ago
6-K
NEUTRAL ★ 2/10
$26.00 $24.25▼ −6.73%▼ −8.39%$26.12 (+0.46%)
Showing 10 of 51

US Market Status

Market Open — Closes in 3h 24m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 20, 2026